The data presented here demonstrate that the TRG3 subset of patients benefited from adjuvant treatment and we postulate that this effect was seen, in contrast to the SPACE-FLOT trial, because the R0 resection rate in our cohort was high and the effect of adjuvant chemotherapy with FLOT in our cohort reflects its effect on the elimination of peripheral micrometastases rather than on residual tumor cells at the primary tumor site. This evidence concerns the gene SAMM50 and neoplasm.